Amine Containing Aromatic Group Patents (Class 424/78.16)
-
Patent number: 7655630Abstract: The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.Type: GrantFiled: August 29, 2008Date of Patent: February 2, 2010Assignee: Shire LLCInventors: Travis Mickle, Suma Krishnan, Barney Bishop, Christopher Lauderback, James Scott Moncrief, Robert Oberlender, Thomas Piccariello, Bernhard J. Paul, Christopher A. Verbicky
-
Patent number: 7628985Abstract: Pharmaceutical formulations of glutenase enzymes are provided. The enzymes find particular use in the treatment of a Celiac or dermatitis herpetiformis patient.Type: GrantFiled: February 23, 2005Date of Patent: December 8, 2009Assignees: The Board of Regents of the Leland Stanford Junior University, Alvine Pharmaceuticals, Inc.Inventors: Lu Shan, Michael Thomas Bethune, Chaitan Khosla, Jonathan David Gass
-
Patent number: 7608674Abstract: Anion-binding polymers are described. The anion-binding polymers in some cases are low swelling anion-binding polymers. In some cases, the anion-binding polymers have a pore volume distribution such that a fraction of the polymer is not available for non-interacting solutes above a certain percentage of the MW of the target ion for the polymer. In some cases, the anion-binding polymers are characterized by low ion-binding interference, where the interference is measured in, for example, a gastrointestinal simulant, relative to non-interfering buffer. Pharmaceutical composition, methods of use, and kits are also described.Type: GrantFiled: November 3, 2004Date of Patent: October 27, 2009Assignee: Ilypsa, Inc.Inventors: Eric Connor, Dominique Charmot, Han-Ting Chang, Florence Roger, Gerrit Klaerner, Son Hoai Nguyen, Jonathan Mills, Jerry M. Buysse, Angela Lee, Deidre Madsen, Jun Shao, Michael J. Cope, John Fordtran
-
Publication number: 20080311161Abstract: Methods and compositions are provided for stabilizing polypeptides for oral administration, particularly where enteric delivery is desirable. By administering the polypeptides with a bile sequestering agent, the stability of the polypeptide can be increased. Pharmaceutical formulations for this purpose are provided.Type: ApplicationFiled: October 11, 2006Publication date: December 18, 2008Inventor: Jonathan David Gass
-
Patent number: 7459151Abstract: Phosphate-binding polymers are provided for removing phosphate from the gastrointestinal tract. The polymers are orally administered, and are useful for the treatment of hyperphosphatemia.Type: GrantFiled: December 6, 2005Date of Patent: December 2, 2008Assignee: Genzyme CorporationInventors: Stephen Randall Holmes-Farley, W. Harry Mandeville, III, George M. Whitesides
-
Publication number: 20080253985Abstract: The invention provides methods and compositions for treating hyperlipidemia and disorders associated with hyperlipidemia in a mammal. Compositions useful in the practice of the invention include a microsomal triglyceride transport protein inhibitor (“MTPI”) and at least two other cholesterol lowering drugs selected from the group consisting of a cholesterol absorption inhibitor (“CAI”), a HMG-CoA reductase inhibitor, a bile acid sequestrant, a fibric acid derivative, niacin, and squalene synthetase inhibitor.Type: ApplicationFiled: October 18, 2006Publication date: October 16, 2008Inventor: Gerald L. Wisler
-
Publication number: 20080248070Abstract: A pharmaceutical composition including therapeutically effective amounts of at least one HMG-CoA reductase inhibitor present as a dyhydroxyacid salt and at least one additional therapeutic agent.Type: ApplicationFiled: June 20, 2008Publication date: October 9, 2008Inventor: Josefino B. Tunac
-
Patent number: 7199160Abstract: Antiobestic agents and health foods containing as the active ingredient substances having an effect of adsorbing bile acid in the digestive tract, an effect of inhibiting intestinal circulation or an effect of inhibiting the absorption of exogenous lipids typified by pharmaceutically acceptable anion exchange resins. In particular, antiobestic agents and health foods characterized by lowering body weight and/or visceral fat content without reducing food intake.Type: GrantFiled: October 9, 2001Date of Patent: April 3, 2007Assignee: Mitsubishi Pharma CorporationInventors: Kazuo Suzuki, Shigekazu Nakajima, Shinji Yano
-
Patent number: 7153497Abstract: A dosage form comprising a resin/resinate combination is described. Said dosage form allows optimization of the release rate profile of active ingredients.Type: GrantFiled: March 26, 2002Date of Patent: December 26, 2006Assignee: Rohm and Haas CompanyInventors: Lyn Hughes, Simon Andrew Bellamy, Christina Hann
-
Patent number: 7147845Abstract: The present invention relates to novel antimicrobial silver ion complex resinates. More particularly, the present invention contemplates silver ion complex resinate compositions comprising a silver-thiosulfate ion complex loaded onto an organic anion exchange resin. These silver thiosulfate ion complex resinate compositions are able to release stable antimicrobial silver ion complexes when placed in a saline environment. These antimicrobial silver-ion complex resinates are useful in the treatment and prevention of infections and diseases.Type: GrantFiled: April 14, 2004Date of Patent: December 12, 2006Assignee: BioInterface Technologies, Inc.Inventor: Christopher C. Capelli
-
Patent number: 7087223Abstract: Provided in a phosphate ion adsorbent containing a weakly basic anion exchange resin as an active ingredient which aims at providing preventives and/or remedies for hyperphosphatemia having a high selectivity for the adsorption of phosphate ion and showing an effect of lowering blood phosphorus level and another effect of suppressing phosphorus excretion into the urine.Type: GrantFiled: November 9, 2004Date of Patent: August 8, 2006Assignee: Hisamitsu Pharmaceutical Co., Inc.Inventors: Takeshi Goto, Kazuhisa Yoshitake, Hiroshi Sorimachi, Kazuteru Moriyama
-
Patent number: 7014846Abstract: Phosphate-binding polymers are provided for removing phosphate from the gastrointestinal tract. The polymers are orally administered, and are useful for the treatment of hyperphosphatemia.Type: GrantFiled: January 28, 2004Date of Patent: March 21, 2006Assignee: Genzyme CorporationInventors: Stephen Randall Holmes-Farley, W. Harry Manderville, III, George M. Whitesides
-
Patent number: 6858203Abstract: Phosphate-binding polymers are provided for removing phosphate from the gastrointestinal tract. The polymers are orally administered, and are useful for the treatment of hyperphosphatemia.Type: GrantFiled: December 17, 2002Date of Patent: February 22, 2005Assignee: Genzyme CorporationInventors: Stephen Randall Holmes-Farley, W. Harry Mandeville, III, George M. Whitesides
-
Patent number: 6692734Abstract: The present invention relates to purified platinum complexes in which platinum is coordinated to form a single N,O- or O,O-chelate of an amidomalonate. The chelates, and pharmaceutically acceptable formulations thereof, are useful for the treatment of cancer. The platinum chelates may additionally be linked to one or more functional groups which increases water solubility and/or assists in tumor targeting of the chelate. Examples of tumor targeting moieties include polymers, in which one or more platinum chelates are attached to the polymer backbone via linkers capable of being cleaved in the body, and molecules with a high affinity for receptors which are concentrated or upregulated in tumor tissue and/or the tumor vasculature.Type: GrantFiled: January 4, 2001Date of Patent: February 17, 2004Assignee: Access Pharmaceuticals, Inc.Inventors: Donald R. Stewart, John R. Rice, John V. St. John
-
Publication number: 20040009145Abstract: A method for treating pathogenic toxins in a mammal, such as a human, comprising treating the mammal with a therapeutically effective amount of a polymer comprising a cationic group attached to the polymer backbone. The polymer can be a homopolymer or a copolymer. In one embodiment, the polymer is a copolymer comprising a monomer having a pendant ammonium group and a hydrophobic monomer.Type: ApplicationFiled: December 19, 2002Publication date: January 15, 2004Applicant: GelTex Pharmaceuticals, Inc.Inventors: Richard Fitzpatrick, Chad Cori Huval, Caroline Isabelle Bacon Kurtz, W. Harry Mandeville, Thomas X. Neenan
-
Patent number: 6673338Abstract: The invention provides NO— or NO−-releasing imidate, thioimidate, and amide diazeniumdiolates, in which the N2O2− functional group is bonded to a carbon atom. The invention also provides compositions comprising such diazeniumdiolate compounds, and methods of using such compounds and compositions. The invention further provides a method of preparing NO— or NO−-releasing imidate, thioimidate, and amide diazeniumdiolates.Type: GrantFiled: September 10, 2001Date of Patent: January 6, 2004Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Ernst V. Arnold, Larry K. Keefer, Joseph A. Hrabie
-
Patent number: 6627228Abstract: Polymeric delivery agents, delivery agent compounds and compositions comprising them which are useful in the delivery of active agents are provided. Methods of administration and preparation are provided as well.Type: GrantFiled: October 9, 2001Date of Patent: September 30, 2003Assignee: Emisphere Technologies, Inc.Inventors: Sam J. Milstein, Eugene N. Barantsevitch, Nai Fang Wang, Jun Liao, John E. Smart, Richard D. Conticello, Raphael M. Ottenbrite
-
Publication number: 20030138493Abstract: Biodegradable polymer compositions suitable for intraperitoneal administration to treat a mammalian subject having ovarian cancer are described, wherein the polymer compositions provide extended release of the antineoplastic agent into the peritoneum of the subject. The subject compositions can increase the median survival rate from the cancer by at least about 10%, as compared with the median survival rate obtained by administration of a composition comprising the same dosage of the antineoplastic agent without the biodegradable polymer. Solid articles and methods for treating ovarian cancer are also described.Type: ApplicationFiled: October 4, 2002Publication date: July 24, 2003Inventor: Wenbin Dang
-
Publication number: 20030099597Abstract: Disclosed are novel compositions for embolizing blood vessels which are particularly suited for treating vascular lesions via catheter delivery.Type: ApplicationFiled: October 28, 2002Publication date: May 29, 2003Inventors: Thomas J. Whalen, Chinh N. Tran, Noah M. Roth, Richard J. Greff
-
Patent number: 6566406Abstract: Biocompatible crosslinked polymers, and methods for their preparation and use, are disclosed in which the biocompatible crosslinked polymers are formed from water soluble precursors having electrophilic and nucleophilic groups capable of reacting and crosslinking in situ. Methods for making the resulting biocompatible crosslinked polymers biodegradable or not are provided, as are methods for controlling the rate of degradation. The crosslinking reactions may be carried out in situ on organs or tissues or outside the body. Applications for such biocompatible crosslinked polymers and their precursors include controlled delivery of drugs, prevention of post-operative adhesions, coating of medical devices such as vascular grafts, wound dressings and surgical sealants.Type: GrantFiled: December 3, 1999Date of Patent: May 20, 2003Assignee: Incept, LLCInventors: Chandrashekhar P. Pathak, Amarpreet S. Sawhney, Peter G. Edelman
-
Publication number: 20030091530Abstract: Provided in a phosphate ion adsorbent containing a weakly basic anion exchange resin as an active ingredient which aims at providing preventives and/or remedies for hyperphosphatemia having a high selectivity for the adsorption of phosphate ion and showing an effect of lowering blood phosphorus level and another effect of suppressing phosphorus excretion into the urine.Type: ApplicationFiled: September 12, 2002Publication date: May 15, 2003Inventors: Takeshi Goto, Kazuhisa Yoshitake, Hiroshi Sorimachi, Kazuteru Moriyama
-
Patent number: 6432417Abstract: Cosmetic composition for the skin or skin appendages comprising a dispersion of solid organic particles in a binder and characterized in that at least a part of said organic particles is introduced in said composition in the form of particles having their surface coated with at least one cationic polymer. The cationic polymer comprises, for example, units containing primary, secondary, tertiary and/or quaternary amine groupings. The particles coated in this way are readily dispersible, even in fatty binders. The cosmetic compositions obtained show good adhesion to the skin and, in the case of compacted compositions, good cohesion properties.Type: GrantFiled: April 21, 1995Date of Patent: August 13, 2002Assignee: L'OrealInventors: Myriam Mellul, Didier Candau
-
Publication number: 20020035089Abstract: A pharmaceutical combination or composition containing a lipase inhibitor, preferably orlistat, and a bile acid sequestrant is useful for treating obesity.Type: ApplicationFiled: July 25, 2001Publication date: March 21, 2002Inventors: Pierre Barbier, Paul Hadvary, Hans Lengsfeld